title: Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up.
abstract: OBJECTIVE
  The objective of this study is to evaluate the one-year outcome of the first 50 patients who underwent nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our institution.
  
  
  BACKGROUND
  Left ventricular outflow tract obstruction is an important determinant of clinical symptoms in patients with hypertrophic obstructive cardiomyopathy. Nonsurgical septal reduction is a new therapy that has been shown to result in left ventricular outflow tract gradient reduction and resolution of symptoms immediately after the procedure and on midterm follow-up.
  
  
  METHODS
  Fifty patients with hypertrophic obstructive cardiomyopathy who underwent nonsurgical septal reduction at our institution and completed 1-year follow-up are described. Complete history, physical examination, two-dimensional echocardiography with Doppler and exercise treadmill testing have been analyzed.
  
  
  RESULTS
  The mean age of the study group was 53 +/- 17 years. All patients had refractory symptoms before enrollment. Ninety-four percent had class III or IV New York Heart Association class symptoms at baseline compared to none at 1 year (p < 0.001). The exercise duration increased by 136 s at 1 year (p < 0.021). Only 20% of patients were either receiving beta-blockers or calcium-channel blockers on follow-up. The resting left ventricular outflow tract gradient decreased from 74 +/- 23 mm Hg to 6 +/- 18 mm Hg (p < 0.01) and from 84 +/- 28 mm Hg to 30 +/- 33 mm Hg (p < 0.01) in patients with dobutamine-provoked gradient at one year. These changes are associated with decreased septal thickness and preserved systolic function.
  
  
  CONCLUSIONS
  Nonsurgical septal reduction therapy is an effective therapy for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence of the favorable outcome up to one year after the procedure.
authors.affiliation: Baylor College of Medicine, Department of Medicine, Houston, Texas, USA.
authors.forename: N M
authors.initials: NM
authors.lastname: Lakkis
authors.forename: S F
authors.initials: SF
authors.lastname: Nagueh
authors.forename: J K
authors.initials: JK
authors.lastname: Dunn
authors.forename: D
authors.initials: D
authors.lastname: Killip
authors.forename: W H
authors.initials: WH
authors.lastname: Spencer
mesh_terms: D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D000529:Complementary Therapies / Q000379:methods*; D015150:Echocardiography, Doppler; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006346:Heart Septum / Q000187:drug effects*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D014694:Ventricular Outflow Obstruction / Q000209:etiology
chemical_list: D000431:Ethanol